Use of Tocilizumab to Treat Arthritis Associated with Mixed Connective Tissue Disease Complicated by Ovarian Teratoma: A Case Report

Haruka Ota, Toru Igarashi, Ryosuke Matsui, Hikaru Takeshita, Koji Hashimoto, Masaki Miyao, Norio Motoda, Tsubasa Takahashi, Jun Hayakawa, Makoto Migita, Yasuhiko ItohJournal of Nippon Medical School 2024 · DOI

Abstract

Mixed connective tissue disease (MCTD) is characterized by mixed features of systemic lupus erythematosus, systemic sclerosis, and polymyositis/dermatomyositis and is rare in children. Here, we report a case of MCTD in a 10-year-old girl who presented at our hospital with arthralgia, Raynaud's phenomenon, and fatigue. Blood tests were positive for anti-U1-ribonucleoprotein (RNP) antibodies and for rheumatoid factors (RFs) IgG-RF and anti-galactose-deficient IgG. Levels of myogenic enzymes and hypergammaglobulinemia were elevated. Macrophages were prominent in bone marrow, with scattered phagocytic macrophages. MCTD was diagnosed based on the patient's symptoms and laboratory findings. Methylprednisolone pulse therapy combined with oral tacrolimus was administered, which led to resolution of symptoms. Three months after pulse therapy, arthralgia worsened and methotrexate was administered. Arthralgia improved but did not resolve. Magnetic resonance imaging performed to investigate the hip pain revealed a mature ovarian teratoma, which was surgically removed. Because the pain persisted and interfered with her daily life, she was treated with tocilizumab for joint pain relief, which decreased the pain level. Tocilizumab is a candidate for additional treatment of juvenile idiopathic arthritis-like arthritis associated with childhood-onset MCTD.

Introduction

Mixed Connective Tissue Disease (MCTD) is a rare autoimmune "overlap" syndrome, combining clinical features of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and polymyositis/dermatomyositis (PM/DM). A defining serological feature is the presence of high titers of anti-U1-ribonucleoprotein (RNP) antibodies. In the pediatric population, MCTD is exceptionally rare, with an estimated incidence of approximately 0.33 per 100,000 children in Japan.

While standard management involves corticosteroids and conventional disease-modifying antirheumatic drugs (DMARDs) like methotrexate (MTX) or tacrolimus, a subset of pediatric patients experiences persistent, debilitating arthritis that mimics Juvenile Idiopathic Arthritis (JIA). This case report describes a 10-year-old girl with MCTD and a co-occurring mature ovarian teratoma, whose refractory joint pain was successfully managed with the IL-6 inhibitor tocilizumab (TCZ).

Case Presentation

A 10-year-old girl presented with a history of arthralgia, Raynaud's phenomenon, and significant fatigue. Initial laboratory investigations revealed high titers of anti-U1-RNP antibodies (113.7 U/mL) and elevated myogenic enzymes, including creatine kinase (CK) at 1,703 U/L and lactate dehydrogenase (LD) at 566 U/L. She also tested positive for multiple rheumatoid factors (RFs), including IgG-RF and anti-galactose-deficient IgG. Bone marrow aspiration showed prominent macrophages with scattered phagocytic activity, though criteria for macrophage activation syndrome were not fully met. Based on these findings, a diagnosis of MCTD was established.

Clinical Course and Management

The patient was initially treated with methylprednisolone pulse therapy (MPT) followed by oral prednisolone (PSL) and tacrolimus. While this induction therapy stabilized her systemic markers and muscle enzymes, her arthralgia persisted. Three months later, methotrexate (8 mg/week) was added due to worsening joint pain.

During an investigation into persistent hip pain, magnetic resonance imaging (MRI) incidentally identified a 6.5 x 5.5 cm mass in the right ovary. The mass was surgically removed on Day 138.

Clinical course and laboratory data over 415 days.

Histopathological Findings

Histopathological examination of the excised ovarian mass confirmed the diagnosis of a mature cystic teratoma. The specimen contained a diverse array of mature tissues derived from all three germ layers, including sebaceous glands, neural tissue, intestinal mucosa, bone, and cartilage.

Histopathological examination of the ovarian mass confirming a mature teratoma.

Response to Biological Therapy

Following the surgical removal of the teratoma, the patient’s arthralgia did not resolve, suggesting that the MCTD was not a paraneoplastic phenomenon. Her joint pain remained severe enough to interfere with daily activities, such as turning a water tap or attending school.

Given the "JIA-like" nature of her arthritis and the known role of Interleukin-6 (IL-6) in such inflammatory pathways, tocilizumab (TCZ) was initiated at a dose of 8 mg/kg every four weeks. Following the first administration, the patient reported a significant reduction in pain. This clinical improvement allowed her to resume normal school activities and significantly enhanced her quality of life.

Discussion

This case highlights several critical aspects of pediatric MCTD management. First, it underscores the potential role of IL-6 in the pathogenesis of MCTD-associated arthritis. The successful use of tocilizumab suggests that IL-6 receptor blockade can be an effective strategy for refractory joint symptoms that do not respond to conventional DMARDs.

Second, the co-occurrence of a mature ovarian teratoma in a pediatric MCTD patient is rare. While autoimmune diseases in adults can sometimes present as paraneoplastic syndromes, the persistence of symptoms post-resection in this case indicates that the MCTD and the tumor were likely independent co-morbidities.

Finally, the presence of multiple RF variants may serve as a clinical marker for a more aggressive, JIA-like joint involvement within the MCTD spectrum, necessitating early consideration of biological therapies.

Conclusion

Tocilizumab represents a promising therapeutic option for managing refractory arthritis in childhood-onset MCTD. While systemic markers may respond to standard immunosuppression, biological agents targeting specific inflammatory cytokines like IL-6 may be necessary to address debilitating joint pain and improve functional outcomes in these complex patients. Further studies are needed to establish standardized treatment protocols for this rare pediatric condition.

Summary updated

Abstract

Mixed connective tissue disease (MCTD) is characterized by mixed features of systemic lupus erythematosus, systemic sclerosis, and polymyositis/dermatomyositis and is rare in children. Here, we report a case of MCTD in a 10-year-old girl who presented at our hospital with arthralgia, Raynaud's phenomenon, and fatigue. Blood tests were positive for anti-U1-ribonucleoprotein (RNP) antibodies and for rheumatoid factors (RFs) IgG-RF and anti-galactose-deficient IgG. Levels of myogenic enzymes and hypergammaglobulinemia were elevated. Macrophages were prominent in bone marrow, with scattered phagocytic macrophages. MCTD was diagnosed based on the patient's symptoms and laboratory findings. Methylprednisolone pulse therapy combined with oral tacrolimus was administered, which led to resolution of symptoms. Three months after pulse therapy, arthralgia worsened and methotrexate was administered. Arthralgia improved but did not resolve. Magnetic resonance imaging performed to investigate the hip pain revealed a mature ovarian teratoma, which was surgically removed. Because the pain persisted and interfered with her daily life, she was treated with tocilizumab for joint pain relief, which decreased the pain level. Tocilizumab is a candidate for additional treatment of juvenile idiopathic arthritis-like arthritis associated with childhood-onset MCTD.
BibTeX
@article{ota2024use,
  author = {Haruka Ota and Toru Igarashi and Ryosuke Matsui and Hikaru Takeshita and Koji Hashimoto and Masaki Miyao and Norio Motoda and Tsubasa Takahashi and Jun Hayakawa and Makoto Migita and Yasuhiko Itoh},
  title = {{Use of Tocilizumab to Treat Arthritis Associated with Mixed Connective Tissue Disease Complicated by Ovarian Teratoma: A Case Report}},
  journal = {Journal of Nippon Medical School},
  year = {2024},
  doi = {10.1272/jnms.jnms.2025\_92-303},
}
Figure